Text Size

Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients

This study has been completed.
Sponsor:
Collaborator:
Millennium Laboratories
Information provided by:
Pain Management Center of Paducah
ClinicalTrials.gov Identifier:
NCT01052155
First received: January 18, 2010
Last updated: March 11, 2011
Last verified: March 2011
History of Changes
  Purpose

Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of Immunoassay and Liquid Chromatography Tandem Mass Spectometry (LC/MS/MS)


Condition Intervention
Chronic Pain
 Other: Urine Drug Testing

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of Immunoassay and Liquid Chromatography Tandem Mass Spectometry (LC/MS/MS)

Resource links provided by NLM:

Drug Information available for: Tandem
U.S. FDA Resources

Further study details as provided by Pain Management Center of Paducah:

Primary Outcome Measures:
  • Diagnostic accuracy [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 1000
Study Start Date: February 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Urine Drug Testing
    LC/MS/MS Laboratory Evaluation
    Other Name: In-office Urine Drug Testing (Immunoassay)
Detailed Description:

Recruitment is indicated in patients with chronic pain management with or without controlled substance therapy.

This is a diagnostic accuracy study performed in an interventional pain management referral center in the United States.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with chronic pain management with or without controlled substance therapy.

Criteria

Inclusion criteria:

• Chronic pain management with or without controlled substance therapy.

Exclusion criteria:

None

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01052155

Sponsors and Collaborators
Pain Management Center of Paducah
Millennium Laboratories
Investigators
Principal Investigator: Laxmaiah Manchikanti, MD Ambulatory Surgery Center, Paducah
  More Information

No publications provided by Pain Management Center of Paducah

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Laxmaiah Manchikanti, MD/Medical Director, Pain Management Center of Paducah and Ambulatory Surgery Center
ClinicalTrials.gov Identifier: NCT01052155     History of Changes
Other Study ID Numbers: Protocol 26
Study First Received: January 18, 2010
Last Updated: March 11, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Pain Management Center of Paducah:
Controlled substances
Opioids
Benzodiazepines
Illicit drugs
 Immunoassay drug testing
Point of care (POC) testing
Liquid Chromatography Tandem Mass Spectometry

ClinicalTrials.gov processed this record on May 21, 2013